+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-17 Targeting Biological Drugs Market - Global Forecast 2026-2032- Product Image
IL-17 Targeting Biological Drugs Market - Global Forecast 2026-2032- Product Image
Sale

IL-17 Targeting Biological Drugs Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6138681
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IL-17 Targeting Biological Drugs Market is projected to reach USD 17.79 Billion in 2026. It is expected to continue growing at a CAGR of 9.15%, reaching USD 29.94 Billion by 2032.

IL-17 Targeting Biological Drugs: Executive Overview

IL-17 targeting biological drugs are an established class of advanced therapies used primarily in immune-mediated inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. Their clinical value is associated with targeted pathway inhibition, rapid symptom control in relevant indications, and the potential to address disease domains that are inadequately managed by conventional systemic treatments. Market development is shaped by evidence generation, regulatory decisions, reimbursement access, treatment guidelines, and the practical requirements of long-term biologic care.

How Treatment Paradigms Are Shifting

The therapeutic landscape is moving toward more selective, outcome-oriented treatment strategies. Clinicians increasingly weigh speed of response, durability, safety monitoring, comorbidity profiles, dosing convenience, and patient preferences when selecting biologic therapy. Expansion across indications is accompanied by stronger emphasis on comparative evidence, persistence, real-world effectiveness, and coordinated management of skin, joint, and axial manifestations. Biosimilar policy, formulary management, and healthcare-system capacity are also influencing access and prescribing behavior.

Artificial Intelligence Is Reshaping Development and Care

Artificial intelligence can support IL-17 drug development by improving trial recruitment, identifying clinically relevant patient subgroups, analyzing longitudinal medical records, and detecting safety signals across heterogeneous data sources. In clinical practice, machine-learning tools may assist with disease-activity assessment, treatment-response monitoring, adherence support, and prioritization of follow-up. These applications remain dependent on representative datasets, transparent validation, privacy safeguards, clinician oversight, and alignment with regulatory requirements; AI should complement rather than replace medical judgment.

Regional Differences Define Access and Adoption

North America combines sophisticated specialty-care infrastructure with rigorous payer review and increasing attention to treatment value. Europe is shaped by centralized or coordinated health-technology assessment, national reimbursement decisions, and guideline-based sequencing. Asia-Pacific presents highly varied regulatory pathways, healthcare capacity, and biologic accessibility, with Japan, South Korea, Australia, China, and India operating under distinct conditions. Latin America is influenced by public-sector procurement, private insurance coverage, and uneven specialist distribution. In the Middle East, GCC systems generally have stronger tertiary-care capacity than many neighboring markets, while access varies across the broader region. Africa faces substantial differences in diagnosis, specialist availability, financing, cold-chain capability, and continuity of care.

Economic and Policy Groups Reveal Common Priorities

ASEAN countries share interest in improving specialty-care access but differ considerably in reimbursement, regulatory maturity, and biologic procurement. BRICS members reflect diverse approaches to domestic manufacturing, public purchasing, regulatory review, and affordability. European Union systems coordinate around scientific and regulatory standards while retaining national decisions on reimbursement and service delivery. G7 countries tend to have mature clinical research and pharmacovigilance systems, alongside close scrutiny of affordability and health-system value. GCC members commonly emphasize centralized procurement, specialist expansion, and advanced hospital capacity. NATO countries do not constitute a single healthcare market, but their members often share priorities around resilient supply chains, emergency preparedness, and continuity of essential medicines.

Country-Level Conditions Require Tailored Strategies

Australia and Canada combine advanced clinical systems with geographically dispersed populations and formal reimbursement assessment. The United States has broad specialist capacity but complex payer rules and substantial variation in coverage. Brazil and Mexico balance private-sector access with public-system needs, while India faces marked differences between metropolitan and rural care. China is expanding innovative-medicine capabilities alongside centralized purchasing and evolving reimbursement mechanisms. Japan and South Korea have structured regulatory and reimbursement environments with strong specialist networks. France, Germany, Italy, and Spain operate within European frameworks but differ in assessment, hospital procurement, and regional implementation. The United Kingdom emphasizes evidence-led commissioning and national guidance. Russia’s access environment is shaped by domestic policy, procurement conditions, and supply considerations.

Priorities for Leaders in IL-17 Biologic Therapy

Industry leaders should align evidence plans with the outcomes that matter to regulators, payers, clinicians, and patients, including functional improvement, sustained disease control, safety, treatment persistence, and quality of life. They should build indication-specific value dossiers, prepare for biosimilar and procurement dynamics, and use real-world evidence responsibly to clarify effectiveness across comorbidities and care settings. Regional operating models should reflect local reimbursement, distribution, diagnostic capacity, and cold-chain requirements. Investment in clinician education, patient-support services, adherence measurement, pharmacovigilance, and validated digital tools can improve responsible adoption. AI initiatives should begin with narrowly defined use cases, measurable performance criteria, governance controls, and human review.

Research Methodology for a Reliable Executive Assessment

This assessment uses a structured review of the IL-17 targeting biological-drug landscape, organized around therapeutic use, clinical evidence, regulation, reimbursement, healthcare delivery, technology adoption, and geographic conditions. Regional, group, and country comparisons are interpreted qualitatively using publicly documented healthcare-system characteristics and established policy considerations. The analysis distinguishes verified structural trends from areas where evidence is heterogeneous, avoids unsupported numerical claims, and treats artificial intelligence as an enabling capability rather than a substitute for clinical or market validation. Findings should be refreshed as guidelines, regulatory decisions, reimbursement policies, and evidence bases evolve.

Conclusion: Targeted Innovation Must Be Matched by Access Discipline

IL-17 targeting biological drugs occupy an important role in modern management of immune-mediated inflammatory disease, supported by pathway-specific clinical utility and continuing evidence development. Future progress will depend less on therapeutic innovation alone than on demonstrating durable value, improving equitable access, navigating regional policy differences, and integrating digital and AI capabilities responsibly. Leaders that connect clinical evidence with patient-centered delivery, resilient supply, and locally appropriate reimbursement strategies will be better positioned to support sustainable use across diverse healthcare systems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IL-17 Targeting Biological Drugs Market, by Target Class
7.1. Introduction
7.2. IL-17A Targeting
7.3. IL-17 Receptor Targeting
7.4. IL-17A/F Dual Targeting
7.5. IL-17F Targeting
8. IL-17 Targeting Biological Drugs Market, by Indication
8.1. Introduction
8.2. Ankylosing Spondylitis
8.3. Juvenile Idiopathic Arthritis
8.4. Plaque Psoriasis
8.5. Psoriatic Arthritis
9. IL-17 Targeting Biological Drugs Market, by Drug Class
9.1. Introduction
9.2. Fusion Protein
9.3. Monoclonal Antibody
10. IL-17 Targeting Biological Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
10.3.1. Auto Injector
10.3.2. Prefilled Syringe
11. IL-17 Targeting Biological Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Distributor
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
11.5.1. Chain Pharmacy
11.5.2. Independent Pharmacy
12. IL-17 Targeting Biological Drugs Market, by End User
12.1. Introduction
12.2. Home Care Setting
12.3. Hospital
12.3.1. Private Hospital
12.3.2. Public Hospital
12.4. Specialty Center
13. IL-17 Targeting Biological Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. IL-17 Targeting Biological Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. IL-17 Targeting Biological Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. ACELYRIN, Inc.
17.3. Affibody Medical AB
17.4. Amgen, Inc.
17.5. AstraZeneca PLC
17.6. Bausch Health Companies Inc.
17.7. DICE Therapeutics, Inc.
17.8. Eli Lilly and Company
17.9. Jiangsu Hengrui Medicine Co., Ltd.
17.10. Kyowa Kirin Co., Ltd.
17.11. LEO Pharma AS
17.12. Mabpharm Ltd.
17.13. MoonLake Immunotherapeutics AB
17.14. Novartis AG
17.15. PJSC BIOCAD
17.16. Sanoosa Pty Ltd.
17.17. Shanghai Junshi Biosciences Co., Ltd.
17.18. UCB S.A.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global IL-17 Targeting Biological Drugs Market, Years Considered for the Study
FIGURE 2. Global IL-17 Targeting Biological Drugs Market, Research Design
FIGURE 3. Global IL-17 Targeting Biological Drugs Market, Research Framework
FIGURE 4. Global IL-17 Targeting Biological Drugs Market, Data Triangulation
FIGURE 5. Global IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global IL-17 Targeting Biological Drugs Market Size, by Target Class, 2025 vs 2032 (%)
FIGURE 7. Global IL-17 Targeting Biological Drugs Market Size, by Target Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global IL-17 Targeting Biological Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global IL-17 Targeting Biological Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 11. Global IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global IL-17 Targeting Biological Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global IL-17 Targeting Biological Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global IL-17 Targeting Biological Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global IL-17 Targeting Biological Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global IL-17 Targeting Biological Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global IL-17 Targeting Biological Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global IL-17 Targeting Biological Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global IL-17 Targeting Biological Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global IL-17 Targeting Biological Drugs Market Segmentation & Coverage
TABLE 2. Global IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 4. Global IL-17A Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global IL-17A Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global IL-17A Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global IL-17 Receptor Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global IL-17 Receptor Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global IL-17 Receptor Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global IL-17A/F Dual Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global IL-17A/F Dual Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global IL-17A/F Dual Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global IL-17F Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global IL-17F Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global IL-17F Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Ankylosing Spondylitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Ankylosing Spondylitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Ankylosing Spondylitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Juvenile Idiopathic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Juvenile Idiopathic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Juvenile Idiopathic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Plaque Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 30. Global Fusion Protein Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Fusion Protein Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Fusion Protein Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 37. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Auto Injector Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Auto Injector Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Auto Injector Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 50. Global Distributor Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Distributor Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Distributor Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 69. Global Home Care Setting Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Home Care Setting Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Home Care Setting Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Specialty Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Specialty Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Specialty Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 95. North America IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. North America IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 97. North America IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. North America IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 99. North America IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. North America IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 101. North America IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. North America IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 103. North America IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. North America IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 105. Latin America IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Latin America IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 107. Latin America IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 108. Latin America IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 109. Latin America IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. Latin America IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 111. Latin America IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Latin America IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 113. Latin America IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Latin America IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 115. Europe IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Europe IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 117. Europe IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 118. Europe IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 119. Europe IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. Europe IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 121. Europe IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Europe IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 123. Europe IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. Europe IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 125. Middle East IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Middle East IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 127. Middle East IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. Middle East IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 129. Middle East IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 130. Middle East IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 131. Middle East IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Middle East IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 133. Middle East IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. Middle East IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 135. Africa IL-17 Targeting Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Africa IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 137. Africa IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 138. Africa IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 139. Africa IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 140. Africa IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 141. Africa IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. Africa IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 143. Africa IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. Africa IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 145. Global IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. ASEAN IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. ASEAN IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 148. ASEAN IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. ASEAN IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 150. ASEAN IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. ASEAN IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 152. ASEAN IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. ASEAN IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 154. ASEAN IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. ASEAN IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 156. GCC IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. GCC IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 158. GCC IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. GCC IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 160. GCC IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. GCC IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 162. GCC IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. GCC IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 164. GCC IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. GCC IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 166. European Union IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. European Union IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 168. European Union IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. European Union IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 170. European Union IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. European Union IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 172. European Union IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. European Union IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 174. European Union IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. European Union IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 176. BRICS IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. BRICS IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 178. BRICS IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. BRICS IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. BRICS IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. BRICS IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 182. BRICS IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. BRICS IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 184. BRICS IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. BRICS IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 186. G7 IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. G7 IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 188. G7 IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. G7 IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 190. G7 IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. G7 IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 192. G7 IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. G7 IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 194. G7 IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. G7 IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 196. NATO IL-17 Targeting Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. NATO IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 198. NATO IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 199. NATO IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 200. NATO IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. NATO IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 202. NATO IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. NATO IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 204. NATO IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. NATO IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 206. Global IL-17 Targeting Biological Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 207. United States IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 208. United States IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 209. United States IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 210. United States IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 211. United States IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. United States IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 213. United States IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. United States IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 215. United States IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. United States IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 217. Canada IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 218. Canada IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 219. Canada IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. Canada IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 221. Canada IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. Canada IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 223. Canada IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. Canada IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 225. Canada IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Canada IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 227. Mexico IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 228. Mexico IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 229. Mexico IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 230. Mexico IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 231. Mexico IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. Mexico IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 233. Mexico IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Mexico IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 235. Mexico IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Mexico IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 237. Brazil IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 238. Brazil IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 239. Brazil IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Brazil IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 241. Brazil IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. Brazil IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 243. Brazil IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Brazil IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 245. Brazil IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. Brazil IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 247. United Kingdom IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 248. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 249. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 251. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 253. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 255. United Kingdom IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. United Kingdom IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 257. Germany IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 258. Germany IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 259. Germany IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. Germany IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 261. Germany IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. Germany IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 263. Germany IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 264. Germany IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 265. Germany IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. Germany IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 267. France IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 268. France IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 269. France IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 270. France IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 271. France IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. France IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 273. France IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. France IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 275. France IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. France IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 277. Russia IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 278. Russia IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 279. Russia IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 280. Russia IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 281. Russia IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 282. Russia IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 283. Russia IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Russia IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 285. Russia IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. Russia IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 287. Italy IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 288. Italy IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 289. Italy IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 290. Italy IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 291. Italy IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 292. Italy IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 293. Italy IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 294. Italy IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 295. Italy IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Italy IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 297. Spain IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 298. Spain IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 299. Spain IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 300. Spain IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 301. Spain IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 302. Spain IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 303. Spain IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Spain IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 305. Spain IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 306. Spain IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 307. China IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 308. China IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 309. China IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 310. China IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 311. China IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. China IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 313. China IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 314. China IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 315. China IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 316. China IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 317. India IL-17 Targeting Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 318. India IL-17 Targeting Biological Drugs Market Size, by Target Class, 2017-2032 (USD Million)
TABLE 319. India IL-17 Targeting Biological Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 320. India IL-17 Targeting Biological Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 321. India IL-17 Targeting Biological Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 322. India IL-17 Targeting Biological Drugs Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 323. India IL-17 Targeting Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 324. India IL-17 Targeting Biological Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 325. India IL-17 Targeting Biological Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 326. India IL-17 Targeting Biological Drugs Market Size, by Hospital, 2017-2032 (USD Millio

Companies Mentioned

  • AbbVie Inc.
  • ACELYRIN, Inc.
  • Affibody Medical AB
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • DICE Therapeutics, Inc.
  • Eli Lilly and Company
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • LEO Pharma AS
  • Mabpharm Ltd.
  • MoonLake Immunotherapeutics AB
  • Novartis AG
  • PJSC BIOCAD
  • Sanoosa Pty Ltd.
  • Shanghai Junshi Biosciences Co., Ltd.
  • UCB S.A.

Related Topics

Related Reports

Living Biological Drugs Market - Global Forecast 2026-2032 - Product Image

Living Biological Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Biological Drugs - Global Strategic Business Report - Product Image

Biological Drugs - Global Strategic Business Report

  • Report
  • 262 Pages
  • Global
From
Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 19-20, 2026) - Product Image

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 19-20, 2026)

  • Training
  • 2 Days
  • Global
Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 18-19, 2027) - Product Image

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 18-19, 2027)

  • Training
  • 2 Days
  • Global
Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2026-2032 - Product Image

Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.